Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • 2025-05
  • 2025-04

    • Angiotensin (1-7) Mechanisms, Clinical Value, and Research P

    2025-09-17

    Angiotensin (1-7): Mechanisms, Clinical Value, and Research Perspectives in Cardiovascular and Renal Therapeutics
    Introduction [Related: anhydrotetracycline hydrochloride]
    Angiotensin (1-7) [Ang-(1-7)] is a heptapeptide hormone derived from the renin-angiotensin system (RAS), recognized for its counter-regulatory effects against the classical angiotensin II (Ang II) axis. Unlike Ang II, which promotes vasoconstriction, inflammation, and fibrosis, Ang-(1-7) exerts vasodilatory, anti-inflammatory, and anti-fibrotic actions, primarily through activation of the Mas receptor (Santos et al., 2003, Circulation Research). The peptide is generated from angiotensin I or II via endopeptidases such as neprilysin and angiotensin-converting enzyme 2 (ACE2), positioning it as a crucial modulator within the RAS (Ferreira et al., 2012, Peptides). The mechanism of action of Ang-(1-7) involves binding to the G protein-coupled Mas receptor, leading to downstream signaling cascades that promote nitric oxide (NO) release, inhibit reactive oxygen species (ROS) production, and suppress pro-inflammatory cytokine expression (Santos et al., 2018, Hypertension). These properties have spurred interest in Ang-(1-7) as a therapeutic candidate for cardiovascular, renal, and metabolic diseases, where RAS imbalance is implicated. [Related: blebbistatin myosin]
    Clinical Value and Applications [Related: erastin price]
    The clinical value of Ang-(1-7) lies in its ability to counteract the deleterious effects of Ang II, offering a novel approach for diseases characterized by RAS overactivity. Its primary applications include:
    1. **Cardiovascular Disorders:** Ang-(1-7) has demonstrated efficacy in reducing hypertension, attenuating cardiac remodeling, and improving endothelial function. Its vasodilatory and anti-fibrotic effects make it a promising adjunct or alternative to conventional RAS inhibitors (Santos et al., 2018).
    2. **Renal Protection:** In models of diabetic nephropathy and chronic kidney disease, Ang-(1-7) reduces proteinuria, glomerulosclerosis, and renal inflammation, suggesting a renoprotective role (Pinheiro et al., 2004, Kidney International).
    3. **Metabolic Syndrome and Diabetes:** By improving insulin sensitivity and reducing oxidative stress, Ang-(1-7) may mitigate the progression of metabolic syndrome and its cardiovascular complications (Santos et al., 2018).
    4. **Pulmonary and Fibrotic Diseases:** Ang-(1-7) exhibits anti-fibrotic actions in lung tissue, with potential implications for pulmonary hypertension and idiopathic pulmonary fibrosis (Shenoy et al., 2010, American Journal of Respiratory and Critical Care Medicine).
    5. **Neurological Disorders:** Emerging evidence points to neuroprotective effects, including reduced neuroinflammation and improved cognitive function in models of stroke and neurodegeneration (Zhou et al., 2015, Neuroscience Letters).
    Key Challenges and Pain Points Addressed
    Current RAS-targeted therapies, such as ACE inhibitors and angiotensin receptor blockers (ARBs), primarily suppress Ang II activity but do not enhance the protective arm of the RAS. This limitation can result in incomplete therapeutic efficacy and adverse effects, such as persistent hypertension, residual proteinuria, and progression of organ damage (Ferrario et al., 2005, Hypertension). Ang-(1-7) addresses several pain points in existing treatments:
    - **Incomplete RAS Modulation:** By directly activating the Mas receptor, Ang-(1-7) restores balance within the RAS, providing benefits beyond Ang II inhibition.
    - **Organ Protection:** Its anti-fibrotic and anti-inflammatory properties offer organ-specific protection, particularly in the heart and kidneys, where conventional therapies may fall short.
    - **Metabolic Benefits:** Ang-(1-7) improves insulin sensitivity and glucose metabolism, addressing the metabolic side effects associated with some RAS inhibitors.
    - **Reduced Adverse Effects:** As a physiological peptide, Ang-(1-7) may have a more favorable safety profile compared to synthetic small-molecule inhibitors.
    Literature Review
    A growing body of preclinical and clinical research supports the therapeutic potential of Ang-(1-7):
    1. **Santos et al. (2003, Circulation Research):** This seminal study identified the Mas receptor as the functional receptor for Ang-(1-7), demonstrating its role in mediating vasodilatory and anti-proliferative effects in vascular tissues.
    2. **Pinheiro et al. (2004, Kidney International):** In a rat model of diabetic nephropathy, Ang-(1-7) administration reduced proteinuria, glomerulosclerosis, and renal inflammation, highlighting its renoprotective actions.
    3. **Ferrario et al. (2005, Hypertension):** This review outlined the limitations of conventional RAS blockade and proposed Ang-(1-7) as a key component of the protective RAS axis, with implications for cardiovascular and renal disease management.
    4. **Shenoy et al. (2010, American Journal of Respiratory and Critical Care Medicine):** The authors demonstrated that Ang-(1-7) attenuates lung fibrosis and inflammation in a bleomycin-induced mouse model, supporting its potential in pulmonary diseases.
    5. **Santos et al. (2018, Hypertension):** This comprehensive review summarized the molecular mechanisms and therapeutic applications of Ang-(1-7), emphasizing its clinical relevance in hypertension, heart failure, and metabolic disorders.
    6. **Zhou et al. (2015, Neuroscience Letters):** The study reported neuroprotective effects of Ang-(1-7) in a rat model of cerebral ischemia, including reduced infarct size and improved neurological outcomes.
    7. **Ferreira et al. (2012, Peptides):** This review detailed the enzymatic pathways leading to Ang-(1-7) formation and its physiological roles, providing a framework for therapeutic development.
    Experimental Data and Results
    Experimental studies have elucidated the pharmacological effects of Ang-(1-7) across multiple organ systems:
    - **Cardiovascular System:** In hypertensive rat models, chronic Ang-(1-7) infusion led to significant reductions in systolic blood pressure and cardiac hypertrophy, accompanied by improved endothelial function (Santos et al., 2003). These effects were abrogated by Mas receptor antagonists, confirming receptor specificity.
    - **Renal System:** Pinheiro et al. (2004) demonstrated that Ang-(1-7) administration in diabetic rats reduced urinary albumin excretion by 40%, decreased glomerular fibrosis, and suppressed renal expression of transforming growth factor-beta (TGF-β), a key mediator of fibrosis.
    - **Pulmonary System:** Shenoy et al. (2010) reported that Ang-(1-7) treatment in a bleomycin-induced lung fibrosis model reduced collagen deposition and inflammatory cell infiltration by over 50%, with concomitant decreases in pro-fibrotic cytokines.
    - **Metabolic Effects:** In models of metabolic syndrome, Ang-(1-7) improved glucose tolerance, enhanced insulin signaling in skeletal muscle, and reduced markers of oxidative stress (Santos et al., 2018).
    - **Neuroprotection:** Zhou et al. (2015) found that post-ischemic administration of Ang-(1-7) in rats reduced cerebral infarct volume by 30% and improved behavioral outcomes, effects linked to reduced neuroinflammation and oxidative damage.
    Collectively, these data underscore the multi-organ protective effects of Ang-(1-7), mediated through Mas receptor activation and modulation of key signaling pathways.
    Usage Guidelines and Best Practices
    The use of Ang-(1-7) in research and potential clinical settings requires careful consideration of dosing, administration route, and safety monitoring:
    - **Formulation:** Ang-(1-7) is typically supplied as a lyophilized peptide, reconstituted in sterile water or physiological saline for in vivo or in vitro applications (APExBIO, 2024).
    - **Dosing:** Preclinical studies have utilized doses ranging from 24 to 576 μg/kg/day in animal models, administered via subcutaneous, intravenous, or intraperitoneal routes. Optimal dosing for human use remains under investigation (Santos et al., 2018).
    - **Administration:** Continuous infusion via osmotic minipumps or repeated bolus injections are common in animal studies. For clinical translation, sustained-release formulations or peptide analogs with improved stability are being explored.
    - **Safety and Monitoring:** Ang-(1-7) has shown a favorable safety profile in animal studies, with minimal adverse effects. However, monitoring for hypotension, electrolyte disturbances, and immune responses is recommended, especially in long-term or high-dose regimens.
    - **Combination Therapy:** Ang-(1-7) may be used alongside ACE inhibitors or ARBs to achieve comprehensive RAS modulation. Synergistic effects have been observed in preclinical models, but potential drug interactions should be evaluated.
    - **Storage and Handling:** The peptide should be stored at -20°C or below, protected from light and moisture. Re Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 60 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11472331